A 2025 JAMA Network Open study analyzing two years of paid search results found that 11% of the search keywords or phrases paid for by Novo Nordisk contained the word "weight", even though the drug Ozempic is approved for type 2 diabetes and not for weight loss.
November 04, 2025
high
statistical
Analysis of paid search (sponsored) results purchased by a pharmaceutical manufacturer.
Glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (brand names Ozempic and Wegovy) and tirzepatide (brand name Mounjaro), are medications used to treat type 2 diabetes and obesity.
October 10, 2025
high
temporal
Baseline description of the drug class and common brand examples.
GLP-1 receptor agonist medications (examples include semaglutide marketed as Ozempic and Wegovy, tirzepatide marketed as Mounjaro, and other agents such as Zepbound) mimic the gut hormone glucagon-like peptide-1 (GLP-1) and act by slowing digestion, reducing appetite, and helping to control blood sugar after meals.
January 01, 2025
high
descriptive
Mechanism of action and metabolic effects of GLP-1 receptor agonist medications used for weight loss and glycemic control.
GLP-1 receptor agonist medications (examples include semaglutide, liraglutide, and tirzepatide) mimic endogenous hormones that help regulate blood sugar and appetite.
high
general
Pharmacologic description of the GLP-1 receptor agonist drug class.